Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

被引：112

作者：

Chung, Hyun Cheol

Lopez-Martin, Jose A.

Kao, Stephen Chuan-Hao

Miller, Wilson H.

Ros, Willeke

Gao, Bo

Egorenkov, Vitaly

Shelekhova, Ksenia

Moiseyenko, Vladimir

机构：

[1] Yonsei Univ Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[2] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[3] Chris OBrien Lifehouse, Sydney, NSW, Australia

[4] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Rossy Canc Network, Montreal, PQ, Canada

[5] Netherlands Canc Inst, Amsterdam, Netherlands

[6] Blacktown Hosp, Sydney, NSW, Australia

[7] Dept Innovat Therapeut & Essais Precoc, Gustave Roussy, Villejuif, France

[8] Lung Canc Unit, Meir Med Ctr, Kefar Sava, Israel

[9] Rabin Med Ctr, Petah Tiqwa, Israel

[10] Univ Canc Oncopole, Dept Oncol, Inst Claudius Regaud Inst, Toulouse, France

[11] Oscar Lambret Canc Ctr, Lille, France

[12] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

[13] Merck Co Inc, Upper Gwynedd, PA USA

[14] Merck Co Inc, Rahway, NJ USA

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.8506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

8506

引用

页数：1